Evaluation of Current Practice of Antimicrobial Use and Clinical Outcome in the Management of Pneumonia Among Pediatric Patients Admitted to Jimma Medical Center, Southwest Ethiopia: A Prospective Observational Study
NCT ID: NCT06830915
Last Updated: 2025-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
161 participants
OBSERVATIONAL
2022-02-03
2022-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia
NCT06921993
Predictors of Improvement and Deterioration of Community Acquired Pneumonia in Children
NCT06720441
Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia
NCT01166932
Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy
NCT06125340
Implementing a Combination of Clinical Parameters, Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients
NCT03366454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2.3 Participant Eligibility and Inclusion All pediatric patients admitted to the pediatric ward of the Jimma Medical Center with a diagnosis of pneumonia during the study period were screened for eligibility criteria. Patients aged less than or equal to 18 years admitted to the pediatric wards of Jimma Medical Center with a suspected or proven pneumonia diagnosis by physician decision on duty during the study period and Patients whose parents gave assent were included in the study. Patients who died before they started antimicrobial, transferred to other facilities and patient lost follow-up were excluded.
2.4 Sample Size and Sampling Technique No sampling technique was applied; instead, all pediatric patients diagnosed with pneumonia that fulfilled illegibility criteria during the study period were recruited in the study. Accordingly, 146 patients were followed and completed data collected.
2.5 Data Collection Instrument and Quality Assurance The data collections instrument (data abstraction format and self-administered questionnaire) was developed by reviewing the literature on antimicrobial use, antimicrobial resistance, and antimicrobial stewardship program guidelines. Training was given for data collectors on the data collection procedure and research objectives. The principal investigator was regularly checking the consistency and completeness of the data and random checks were also being performed.
2.6 Data Processing and Analysis Data was compiled, cleared, coded, and verified for completeness and accuracy before being included in Epi Data Manager version 4.6.2. Double-entry verification was performed and the data was analyzed using statistical software, SPSS version 25.0. Descriptive statistics (mean, frequency, and cross tabulation) were used to describe practice of antimicrobial use. The bivariate logistic regression was performed for clinical outcome and variables with p-values less than 0.25 with outcomes (poor outcome or good outcome) were taken into account for further analysis. Then, the independent predictors were identified by multivariate logistic regression analysis. All statistical tests were detailed; a P value of less than or equal to 0.05 was considered statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation only
No intervention made
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jimma University
OTHER
Bule Hora University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abduba Wariyo Guyo
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jimma University
Jimma, Oromiya, Ethiopia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ref. No. JUIRB016/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.